The effectiveness of the assisted use of SABA on patients with COPD depends on whether LABA is inhaled or not
Hirohisa Kanoa,b Akira Shirakib Morihide Andob Jyunya Nodab Sho Horib Michiko Kagajyob Harunori Nakashimab Takashi Abeb Joe Shindob
aDepartment of Respiratory and Allergy Medicine, Okayama University Hospital
bDepartment of Respiratory Medicine, Ogaki Municipal Hospital
The short-acting beta-2 agonist (SABA) assist use protocol aids patients with chronic obstructive pulmonary disease (COPD). The purpose of this study was to investigate the effect of regularly inhaled long-acting bronchodilators on SABA assist use. Between September 2013 and January 2015, exercise tolerability was evaluated using the incremental shuttle-walking test (ISWT); we tested 72 patients with COPD before and after SABA assist use. In the long-acting muscarinic antagonist (LAMA) group, the difference in walking distance was 14.4±9.3m, whereas in the long-acting beta-2 agonist (LABA) group the distance was 4.1±6.4m. Thus, any improvement in exercise tolerance tended to be minimal in the LABA group. This implies that differences in the periodicity of inhaled medicine may affect the utility of SABA assist use.
Chronic obstructive pulmonary disease (COPD) Short-acting beta-2 agonist (SABA) Assist use Indacaterol Incremental shuttle-walking test (ISWT)
Received 14 Dec 2018 / Accepted 08 Apr 2019
AJRS, 8(4): 229-234, 2019